Serpinc1 RNAi Therapy for Hemophilia Bleeding Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bleeding disorders like hemophilia, especially in subjects with inhibitors, are not completely effective, and there is a need for alternative therapies that can control bleeding events with reduced doses of replacement factors or bypassing agents.
Innovation Solution
Administer a therapeutically effective amount of a double-stranded RNAi agent that inhibits Serpinc1 gene expression, combined with a reduced dose of replacement factors or bypassing agents, to treat bleeding events in hemophilia subjects with or without inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (replacement factors or bypassing agents) are used to treat bleeding events in hemophilia subjects, then bleeding control is achieved, but high doses are required which cause increased side effects and treatment complexity
Solution Approach 1:
The patent introduces an RNAi agent as an intermediary substance that targets and reduces inhibitor levels in the blood. This mediator enables the coagulation system to respond more effectively to lower doses of replacement factors or bypassing agents, thereby resolving the contradiction between achieving reliable bleeding control and reducing the quantity of treatment substances required.
Solution Approach 2:
The patent changes the parameter of inhibitor concentration in the blood by administering RNAi agents that specifically target inhibitor mRNA. This parameter change (reducing inhibitor levels) allows for improved sensitivity to replacement factors or bypassing agents, enabling effective bleeding control at lower doses and thus resolving the technical contradiction.
2Reliability
If high doses of replacement factors or bypassing agents are administered to ensure bleeding control, then treatment reliability is improved, but treatment complexity and side effects increase
Solution Approach 1:
The RNAi agent serves as a mediator that modifies the biological environment by reducing inhibitor levels. This creates a more favorable condition for replacement factors or bypassing agents to work effectively at lower doses, thereby simplifying the treatment protocol and reducing side effects while maintaining reliability.
Solution Approach 2:
The patent employs preliminary action by administering the RNAi agent before or alongside the replacement factor or bypassing agent. This preliminary modification of the blood environment (reducing inhibitors) prepares the system to respond more effectively to the subsequent treatment, allowing for lower doses and reduced complexity.
3Reliability
If standard doses of replacement factors are used in subjects with inhibitors, then bleeding control is attempted, but treatment effectiveness is significantly reduced due to inhibitor interference
Solution Approach 1:
The patent converts the harmful effect of inhibitors into a benefit by using RNAi agents that specifically target and reduce inhibitor levels. The harmful inhibitors become the target of therapeutic intervention, and their reduction allows replacement factors or bypassing agents to work effectively, thus converting the original harm into a therapeutic advantage.
Solution Approach 2:
The RNAi agent acts as an intermediary that specifically targets and reduces inhibitor levels in the blood. This mediator eliminates the harmful interference of inhibitors, allowing the replacement factors or bypassing agents to exert their full therapeutic effect and thereby improving treatment effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi agent effectively reduces Serpinc1 activity, allowing for the successful treatment of bleeding events with lower doses of replacement factors or bypassing agents, thereby improving treatment efficacy and reducing side effects.
Implementation Method 1
administer a therapeutically effective amount of a double-stranded RNAi agent that inhibits Serpinc1 gene expression
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2A~2B
AI summary
The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpincl gene, and methods of using such iRNA, e.g., dsRNA, compositions to treat a bleeding event in a subject having a hemophilia (e.g., with or without Inhibitors).